Using Bone Marrow-Derived Stem Cells for Tumor Gene Therapy
Author Information
Author(s): Hu M, Yang J-L, Teng H, Jia Y-Q, Wang R, Zhang X-W, Wu Y, Luo Y, Chen X-C, Zhang R, Tian L, Zhao X, Wei Y-Q
Primary Institution: State Key Laboratory of Biotherapy, West China Hospital, Sichuan University
Hypothesis
Systemically delivered bone marrow-derived stromal cells (BMSCs) would preferentially home to tumor tissues and participate in the formation of tumor stroma.
Conclusion
BMSCs can be effectively used as a vehicle for tumor gene therapy, improving the concentration of anticancer therapeutics in tumors and modifying the tumor microenvironment.
Supporting Evidence
- BMSCs expressing sFlt-1 significantly reduced lung metastases in treated mice.
- Treatment with sFlt-1-bearing BMSCs prolonged the lifespan of tumor-bearing mice.
- Angiogenesis was significantly inhibited in tumors treated with BMSCs expressing sFlt-1.
- Apoptosis of cancerous cells was increased in the presence of sFlt-1.
Takeaway
Scientists are using special cells from bone marrow to help deliver cancer-fighting medicine directly to tumors, which helps shrink them and makes mice live longer.
Methodology
BMSCs were genetically modified to express sFlt-1 and tested in mouse models for their ability to inhibit tumor growth and metastasis.
Potential Biases
Potential bias due to the use of animal models and the specific conditions of the experiments.
Limitations
The effects of naive BMSCs on tumor growth and the potential for transformation of BMSCs remain unclear.
Participant Demographics
Male BALB/c and female C57BL/6 mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website